News

While ongoing stress from COVID-19 has had an effect on many people's mental health, contracting the virus may have much more of an impact on the brain.

At a time like this, it is important for providers and health systems to establish an OBGYN communication strategy to ensure existing and prospective patients are aware of the precautions their obstetricians are taking to safely deliver babies and conduct routine appointments for those who are, or plan to become, pregnant.

RAND study puts some numbers to telehealth surge but also shows evidence of disparities along income, racial/ethnic lines.

In this episode, Briana Contreras of MHE spoke with Aaron Fulner, Senior Director of Edifecs, a global health IT company. The two had a conversation about open enrollment and how private and public insurance markets have been preparing or are now experiencing an influx of new enrollees due to approximately 12 million people losing access to employer coverage from job losses since February.

As hospitals and health systems struggle to regain revenue, they will find themselves competing aggressively to attract and retain a smaller pool of patients. It will require doubling down on the patient experience, but will create a larger boost of healthcare consumerization, overall.

While physical and mental effects of Autosomal Dominant Polycystic Kidney Disease are top of mind for those personally impacted, as well as for nephrologists, the financial implications associated with this condition are often overlooked despite the fact that research has confirmed the economic burden of the disease increases over time for both the patient and the healthcare system.

Recalls of metformin products due to higher levels of the probable carcinogenic ingredient N-Nitrosodimethylamine (NDMA) than allowed continue.

Forty-three percent of new cases in nursing homes are coming from midwest states.

Trump jokes about potentially firing NIAID Director Anthony S. Fauci.

What do the two presidential candidates have right in healthcare policy? Where do they both go wrong? And what will it take for payment reform to take off? Michael Abrams of Numerof discusses what comes after Election Day.

Open enrollment has started and the median premium increase is 1.1%, according to the Kaiser Family Foundation.

The Johns Hopkins professor and new MHE editorial advisory board member discusses screening among race, how certain screening tests intensify health disparities and how the Trump administration is not correctly applying science within healthcare in this final part of a four-part video series.

Research from a Doximity survey shows physician wages have grown by only 1.5% amid COVID-19 pandemic, and gender pay gap among doctors persists at 28%.

FDA approves new uses for companion diagnostics, while Janssen seeks a new indication for Xarelto.

With the uptick in claims denials, which have increased sharply due to CARES-related provisions, the onus is on providers to directly address a problem that’s only going to get worse as we continue to work our way through the COVID-19 pandemic. Recommended is a 4-pronged approach for providers to address this.

Falls are the current leading cause of injuries for older Americans, and many of them result in permanent disability and fatalities. The risk of falling for older adults doubles if they have impaired vision from a degenerative eye disease like diabetic retinopathy.

Here's what healthcare executives can expect depending who wins next week's election.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a Q&A interview between MHE and the emerging leader.

CMS's new Interoperability and Patient Access final rule (9115-F)they will be releasing in 2021 is aimed to empower patients and improve interoperability while reducing the burden on payers and providers. However, the process to meet the requirements will be challenging.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

A Biden presidency will mean the immediate expansion of health insurance coverage and perhaps a public option. A second term for President Trump would mean renewed efforts to repeal and replace the ACA and emphasis on consumer choice.

In this episode of Tuning Into the C-Suite, listeners are tuning into our next feature of the Meet the Board series where MHE's Senior Editor, Peter Wehrwein, and Associate Editor, Briana Contreras, speak with Managed Healthcare Executive Editorial Advisory Board Member, Don Hall, who is principal of DeltaSigma LLC. DeltaSigma is a consulting practice specializing in strategic problem solving for managed care organizations. In addition to being a loyal member of our board since 2007, Don most recently served as president and CEO of a nonprofit, provider-sponsored health plan. In this conversation, you’ll learn a bit about Don, personally, such as what he's currently reading, and his thoughts about the current issues healthcare is facing today.

Managed Healthcare Executive's October issue headlines 10 healthcare leaders in its fourth annual "10 Emerging Industry Leaders" feature. MHE spotlights each leader individually with a video interview to accompany the Q&A between MHE and the emerging leader.

According to a new survey provided by the American Psychological Association (APA), more than 68% of U.S. adults say the 2020 U.S. presidential election is a significant source of stress in their life. The APA offers advice on how to handle election stress.

Pfizer, the reputed leader in the COVID-19 vaccine race, may not have efficacy results for awhile. Meanwhile, AstraZeneca and Johnson & Johnson have resuming enrolling volunteers in the U.S. in their late-stage trials.

The treatment is a combination of ublituximab, its investigational glycoengineered anti-CD20 monoclonal antibody, and umbralisib, the company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon.

Medical company secures Investigational New Drug Application from FDA for its gummy medication.